From “NASDAQ”:

The Percept RC Deep Brain Stimulation system by Medtronic is now FDA approved, a breakthrough in healthcare
Medtronic’s Percept allows for personalized treatment and is a game changer for the estimated 11 million Americans with movement disorders. Medtronic is already prepared for a spike in demand, with more innovation on the horizon, for those who want to invest, the Motley Fool Stock Advisor is providing a detailed blueprint for success. CircularProgress returns for their subscribers have been substantial over the years.

Editor: Eric Volkman for the Motley Fool. The Motley Fool suggests at least exploring the 10 top stocks, even though Medtronic wasn’t one of the picks.



Read more: Why Medtronic Stock Got Off to a Roaring Start This Week